Dyax enjoys climbing stock prices

Dyax had a great day Monday. The company released positive late-stage clinical trial findings regarding its drug DX-88 and investors took notice. According to its data, DX-88 reduced the symptoms associated with hereditary angioedema, a genetic blood disorder, and stocks climbed by 15.5 percent, to the company's 2008 peak thus far.  Report

Suggested Articles

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.